Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy

about

Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy

Item

http://www.wikidata.org/entity/Q58800891

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy

@en

Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy

@nl

type

Item

label

Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy

@en

Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy

@nl

prefLabel

Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy

@en

Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy

@nl

P1476

Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy

@en

P2093

Bi-Qin Tan

http://www.w3.org/2001/XMLSchema#string

Bo Zhang

http://www.w3.org/2001/XMLSchema#string

Chong Zhang

http://www.w3.org/2001/XMLSchema#string

Fei Wang

http://www.w3.org/2001/XMLSchema#string

Ke Ding

http://www.w3.org/2001/XMLSchema#string

Neng-Ming Lin

http://www.w3.org/2001/XMLSchema#string

Qing-Yu Li

http://www.w3.org/2001/XMLSchema#string

Xiu Hu

http://www.w3.org/2001/XMLSchema#string

Yang-Ling Li

http://www.w3.org/2001/XMLSchema#string

P2860

ER stress-induced cell death mechanisms

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell Fate

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies.

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Shikonin suppresses ERK 1/2 phosphorylation during the early stages of adipocyte differentiation in 3T3-L1 cells.

Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737.

PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress

P304

3882-3890

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MMR.2018.9347

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30106133

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

molecular medicine

molecular biology

P932

6131653

http://www.w3.org/2001/XMLSchema#string